Vaxcyte, Inc. officer Elvia Cowan filed a Form 144 notice on November 2, 2026, disclosing a proposed sale of 3,000 shares of Vaxcyte common stock on NASDAQ, acquired the same day through the exercise of stock options.
Key Highlights
- Proposed sale: Elvia Cowan, an officer of Vaxcyte, Inc., intends to sell 3,000 shares of common stock with an aggregate market value of $185,640.00.
- Acquisition method: The 3,000 shares were acquired on November 2, 2026, through the exercise of stock options granted by the issuer, with cash payment made the same date.
- Broker: The proposed sale is to be executed through UBS Financial Services, Inc., located at 11 Madison Ave, 4th Floor, New York, NY 10010.
- Prior sales: During the past three months, Cowan sold 19,000 shares of Vaxcyte common stock on October 5, 2026, for gross proceeds of $1,648,060.00.
- Shares outstanding: According to the filing, 148,805,278 shares of Vaxcyte common stock were outstanding at the time of the notice.
- Trading plan: The filing indicates reliance on Rule 10b5-1, with a plan adoption date of December 8, 2025.
Cowan's Proposed Sale Details and Recent Transaction History at Vaxcyte
According to the Form 144 filed with the U.S. Securities and Exchange Commission, Elvia Cowan, identified as an officer of Vaxcyte, Inc. (NASDAQ:PCVX), submitted a notice of proposed sale on November 2, 2026. The filing discloses that Cowan intends to sell 3,000 shares of Vaxcyte common stock, with an aggregate market value reported as $185,640.00. The approximate date of sale listed in the filing is November 2, 2026.
The filing states that the 3,000 shares were acquired on November 2, 2026, via the exercise of stock options from the issuer, with full cash payment made on that same date. The proposed sale is to be conducted through UBS Financial Services, Inc., acting as attorney-in-fact for Cowan. The filing also notes that Cowan's plan was adopted under Rule 10b5-1 on December 8, 2025, meaning the representation required under that rule is made as of the plan adoption date.
In the section covering securities sold during the past three months, the filing discloses that Cowan sold 19,000 shares of Vaxcyte common stock on October 5, 2026, generating gross proceeds of $1,648,060.00. At the time of the notice, the filing reports 148,805,278 shares of Vaxcyte common stock outstanding. Vaxcyte, Inc. is headquartered at 825 Industrial Road, Suite 300, San Carlos, California 94070.
What Was Disclosed
Vaxcyte officer Elvia Cowan filed a Form 144 notice proposing to sell 3,000 shares of common stock with an aggregate market value of $185,640.00, acquired through option exercise on November 2, 2026, under a Rule 10b5-1 plan adopted December 8, 2025.



Please wait processing your request...